Lilly details robust R&D pipeline to investment community
Company states it has the potential to launch 20 new products in the 10 years beginning in 2014 and extending through 2023.
In a presentation to the investment community, Eli Lilly and Company stated it has the potential to launch 20 new products in the 10 years beginning in 2014 and extending through 2023. In addition, Lilly could launch an average of two new indications or line extensions for already-approved products per year during that same time period.
"We're pleased to share with investors the breadth and depth of the Lilly pipeline, which showcases our progress across our key therapeutic areas. This includes recent launches as well as a robust lineup of assets in late-stage development or already under regulatory review," said John C. Lechleiter, Lilly's chairman, president and CEO. "There are no guarantees given the nature of science and of our business; however, in looking at our recent launches and current pipeline, we believe we are in the midst of the most prolific period of new launches in our company's 140-year history."
Lilly's R&D efforts focus on five therapeutic areas where the company has assets and capabilities that enable it to compete successfully. These include four core areas — diabetes, oncology, immunology and neurodegeneration — and one emerging area — pain. Building upon a similar investment community meeting in December 2015 focused on neurodegeneration — specifically Alzheimer's disease — as well as animal health, today's presentation highlighted the company's R&D strategy and progress in diabetes, oncology, immunology and pain.
"We have improved the productivity and success of our pipeline through discrete actions aimed at enhancing focus, quality and speed, and by positioning ourselves as an attractive partner for external innovation opportunities," said Jan Lundberg, executive vice president of science and technology and president of Lilly Research Laboratories. "These improvements have led to the potential for unprecedented R&D output."
Diabetes
Lilly's long-standing commitment to diabetes care dates to 1923, when it was the first company to bring insulin to patients. Today, the company has the broadest range of diabetes therapies in the industry. Lilly's R&D efforts in diabetes focus on differentiated therapeutics and delivery devices within three key areas of unmet need: glucose control, metabolic control and end-organ protection. The company aims to combine its strong in-house diabetes R&D capabilities with a comprehensive external network to deliver continued innovation in this important area of therapy.
Oncology
Lilly has a long history of leadership in oncology. The company has a balanced R&D approach across three key areas of disease modification: tumor cell signaling, tumor microenvironment and immuno-oncology. This approach allows for testing of combinations of internally-derived agents to address tumor heterogeneity and drug resistance. Lilly has a portfolio of differentiated assets across these approaches, including Cyramza® (ramucirumab), Portrazza™ (necitumumab), olaratumab and abemaciclib. Lilly's immuno-oncology portfolio will have five differentiated molecules in clinical testing by the end of 2016, and as many as 11 by the end of 2018.
Immunology
With the recent launch of Taltz® (ixekizumab) and the submission of baricitinib for regulatory review, Lilly has designated immunology as the company's newest core therapeutic area. While these assets represent the foundational first wave of innovation, Lilly has built a robust emerging pipeline of both internal assets and partnered molecules focusing on key pathways and interventions in multiple autoimmune diseases.
Neurodegeneration
Lilly's commitment to Alzheimer's disease is demonstrated by its more than 25 years of research and development in the field. As a result of this sustained effort and deep understanding of the disease, Lilly today has one of the industry's most comprehensive Alzheimer's portfolios, with seven molecules already in human testing. The company's Alzheimer's research includes disease prevention, detection and treatment.
Pain
Pain is an emerging research area for Lilly, focusing on non-opioid treatment for chronic pain. The two late-stage innovative medicines currently in development are galcanezumab (CGRP Ab), being studied for cluster headache and migraine, and tanezumab, being studied for osteoarthritis pain, chronic lower back pain and cancer pain in partnership with Pfizer.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance